Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Everyone with type 1 diabetes will be offered flash or CGM technology free on the NHS in England and Wales: new NICE guidelines published
People with type 1 diabetes will be offered continuous glucose monitoring (CGM), shown here, or flash glucose monitoring. Image: Dexcom.
New guidance for the NHS in England published today has recommended that people with type 1 diabetes be offered a choice of intermittently scanned glucose monitoring (otherwise known as ‘flash’) or real-time continuous glucose monitoring (CGM) on the NHS.
JDRF is delighted that the National Institute for Health and Care Excellence (NICE) is recommending that glucose monitoring devices can now be chosen based first and foremost on a person’s preferences and needs and how well the devices available will meet those needs, such as predictive alerts, uploading to the cloud, pump or smart pen integration and sharing with parents or carers.
Further guidance for children and young people with diabetes also recommends that those with type 1 diabetes be offered CGM, alongside education to support themselves and their families in using it.
The guidelines apply to England and Wales. Scotland and Northern Ireland have their own processes and JDRF is urging equivalent access across all four nations of the UK.
Hilary Nathan, JDRF’s Policy Director said: “This new guidance offers potentially life-changing technologies to everyone living with type 1 in perhaps the most significant change to treatment since home blood glucose monitoring was introduced more than forty years ago. Most importantly, comprehensive NHS access to flash and CGM treatments will substantially reduce health inequalities and improve long term health outcomes for people with type 1 diabetes.”
Dr Sufyan Hussain, Consultant Physician in Diabetes & Endocrinology at St Thomas’ NHS Foundation Trust & King’s College London, and a member of JDRF’s Scientific Advisory Council said: “This is really positive news for people living with and caring for type 1 diabetes. The work ahead needs to ensure we can continue to address the implementation gaps, disparities in care and support people with and carers for type 1 diabetes with the opportunities highlighted in the guidance. We look forward to continuing this journey with all our stakeholders.”
The new guideline has incorporated JDRF’s recommendations to NICE to widen access to type 1 technology. In 2019, JDRF submitted comments to the NICE stakeholder consultation calling for a change in wording that would require healthcare professionals to ‘offer’ rather than ‘consider’ CGM for people with type 1 diabetes who meet the criteria. This amendment has been incorporated into the new guidance.
This guidance has been shaped by the lived experience of the type 1 community, by charities such as JDRF, and by the leadership of Professor Partha Kar and the leading diabetes healthcare professional groups.
Major changes such as those announced today can take time to come into force, and will be implemented at different rates across the country. Previous NICE guidance updates have often been implemented differently across areas of England, meaning the same technologies and treatments are not available in each area. This creates a potential postcode lottery. JDRF will be scrutinising the local implementation of the new guidance to ensure geographical inequality is avoided.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.